Novel Dual-Action Peptide KN069 Shows Promising Safety and Weight Loss in Early Human Trial

The global burden of obesity and overweight continues to rise, driving demand for more effective and safer therapeutic options. Current treatments, such as GLP-1 receptor agonists, have shown significant efficacy, but there's ongoing research into novel mechanisms to enhance metabolic benefits. This study addresses the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of KN069, a novel dual GLP-1R agonist and GIPR antagonist, in male adults with overweight or obesity.

KN069 demonstrated a favorable safety and tolerability profile across all dose groups, with no serious adverse events reported. The most common adverse events were mild and transient gastrointestinal disturbances, affecting 18% of KN069-treated subjects compared to 7% in the placebo group. Pharmacokinetic analysis revealed dose-proportional exposure and a half-life consistent with once-weekly administration. > The most significant finding was a dose-dependent reduction in body weight, with subjects receiving 3 mg of KN069 once weekly for 4 weeks achieving a mean weight loss of 3.6 kg (3.9% of baseline body weight) compared to 0.6 kg (0.6%) in the placebo group (p<0.001). Additionally, the highest dose of KN069 led to a significant reduction in fasting glucose levels by 1.3 mmol/L (p<0.01) and improved insulin sensitivity, indicated by a 25% decrease in HOMA-IR (p<0.05) compared to placebo.